Monopar Therapeutics Inc. (MNPR) Operating cash flow 2016–2025
Monopar Therapeutics Inc. (MNPR) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$12.2MFY2025 · since FY2016: -$1.2M → -$12.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$12.2M | -90.5% |
| FY2024 | -$6.4M | +18.5% |
| FY2023 | -$7.9M | -8.7% |
| FY2022 | -$7.2M | +1.2% |
| FY2021 | -$7.3M | -56.9% |
| FY2020 | -$4.7M | -54.5% |
| FY2019 | -$3.0M | -12.6% |
| FY2018 | -$2.7M | -2.0% |
| FY2017 | -$2.6M | -119.9% |
| FY2016 | -$1.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More MNPR financial trends
MNPR RevenueMNPR Net incomeMNPR Net marginMNPR Gross profitMNPR Gross marginMNPR Operating incomeMNPR Operating marginMNPR Free cash flowMNPR Capital expendituresMNPR Return on equityMNPR Stock buybacksMNPR Dividends paidMNPR Total assetsMNPR Total liabilitiesMNPR Shareholders’ equityMNPR overview →